GRB2 and neoplasm: Tumor growth was significantly decreased in all groups compared to control (mean ± SEM; control: 1.67 g ± 0.30 g; paclitaxel and bevacizumab only: 0.74 ± 0.30 g; L-Grb2 only: 1.18 ± 0.37 g, and paclitaxel, bevacizumab and L-Grb2 group: 0.38g ± 0.25 g) (Supplementary Figure 8A).